Department of Oncological Sciences Icahn Genomics Institute Precision Immunology Institute Tisch Cancer Institute Friedman Brain Institute Icahn School of Medicine at Mount Sinai New York New York USA
Siyu Wang
Department of Oncological Sciences Icahn Genomics Institute Precision Immunology Institute Tisch Cancer Institute Friedman Brain Institute Icahn School of Medicine at Mount Sinai New York New York USA
Diana D. Kang
Department of Oncological Sciences Icahn Genomics Institute Precision Immunology Institute Tisch Cancer Institute Friedman Brain Institute Icahn School of Medicine at Mount Sinai New York New York USA
Yizhou Dong
Department of Oncological Sciences Icahn Genomics Institute Precision Immunology Institute Tisch Cancer Institute Friedman Brain Institute Icahn School of Medicine at Mount Sinai New York New York USA
Abstract Cell therapy has revolutionized the treatment of various diseases, such as cancers, genetic disorders, and autoimmune diseases. Currently, most cell therapy products rely on ex vivo cell engineering, which requires sophisticated manufacturing processes and poses safety concerns. The implementation of in situ cell therapy holds the potential to overcome the current limitations of cell therapy and provides a broad range of applications and clinical feasibility in the future. A variety of biomaterials have been developed to improve the function and target delivery to specific cell types due to their excellent biocompatibility, tunable properties, and other functionalities, which provide a reliable method to achieve in vivo modulation of cell reprogramming. In this article, we summarize recent advances in biomaterials for in situ cell therapy including T cells, macrophages, dendritic cells, and stem cells reprogramming leveraging lipid nanoparticles, polymers, inorganic materials, and other biomaterials. Finally, we discuss the current challenges and future perspectives of biomaterials for in situ cell therapy.
